home / stock / life / life quote
Last: | $1.90 |
---|---|
Change Percent: | -0.54% |
Open: | $1.86 |
Close: | $1.90 |
High: | $1.95 |
Low: | $1.82 |
Volume: | 268,406 |
Last Trade Date Time: | 06/04/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.9 | $1.86 | $1.9 | $1.95 | $1.82 | 268,406 | 06-04-2024 |
$1.85 | $1.82 | $1.85 | $1.87 | $1.8 | 289,674 | 06-03-2024 |
$1.73 | $1.77 | $1.73 | $1.8726 | $1.71 | 210,054 | 05-31-2024 |
$1.76 | $1.69 | $1.76 | $1.83 | $1.65 | 351,641 | 05-30-2024 |
$1.68 | $1.79 | $1.68 | $1.8 | $1.66 | 400,222 | 05-29-2024 |
$1.79 | $1.82 | $1.79 | $1.86 | $1.715 | 208,122 | 05-28-2024 |
$1.8 | $1.8 | $1.8 | $1.8275 | $1.7801 | 113,737 | 05-27-2024 |
$1.8 | $1.8 | $1.8 | $1.8275 | $1.7801 | 113,737 | 05-24-2024 |
$1.8 | $1.89 | $1.8 | $1.9 | $1.77 | 396,244 | 05-23-2024 |
$1.86 | $1.95 | $1.86 | $1.95 | $1.86 | 292,216 | 05-22-2024 |
$1.95 | $2.09 | $1.95 | $2.09 | $1.905 | 387,818 | 05-21-2024 |
$2.07 | $2.01 | $2.07 | $2.09 | $2 | 379,354 | 05-20-2024 |
$2 | $1.92 | $2 | $2.02 | $1.915 | 577,288 | 05-17-2024 |
$1.93 | $1.94 | $1.93 | $1.9685 | $1.8801 | 423,218 | 05-16-2024 |
$1.915 | $1.89 | $1.915 | $1.9988 | $1.87 | 489,107 | 05-15-2024 |
$1.82 | $1.73 | $1.82 | $1.82 | $1.6901 | 413,516 | 05-14-2024 |
$1.7 | $1.72 | $1.7 | $1.75 | $1.68 | 4,636,559 | 05-13-2024 |
$1.69 | $1.71 | $1.69 | $1.735 | $1.669 | 224,343 | 05-10-2024 |
$1.72 | $1.73 | $1.72 | $1.73 | $1.692 | 214,054 | 05-09-2024 |
$1.69 | $1.68 | $1.69 | $1.72 | $1.63 | 271,152 | 05-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...